Fucoidan, as Heparin, Induces Tissue Factor Pathway Inhibitor Release from Cultured Human Endothelial Cells

Summary

Fucoidan, a sulfated polysaccharide extracted from brown seaweeds, has antithrombotic properties, the mechanism of which is not yet completely understood. Tissue factor pathway inhibitor (TFPI), which regulates the tissue factor-dependent pathway of blood coagulation, is released from the endothelium by heparin, a mechanism contributing to its antithrombotic activity. In this study, we demonstrated that fucoidan, as heparin, induces TFPI release from cultured human umbilical vein endothelial cells (HUVEC). The TFPI accumulation in the HUVEC supernatants depends on the incubation time and polysaccharide concentration. After 30 to 60 minutes of incubation, TFPI concentration (total antigen level) was twice higher in the presence of both polysaccharides than in their absence. After one hour of incubation, in the presence of increasing concentrations of each polysaccharide, an optimal stimulation was observed for 0.5 μg/ml of fucoidan and 5 μg/ml of heparin, as evidenced by a raise of the basal TFPI level: a 2-fold increase for the total antigen and a 3-fold increase for the free antigen. These data suggest that TFPI released from vascular endothelial cells may contribute to the antithrombotic effect of fucoidan.

• References

• 1 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
• 2 Kaiser B, Fareed J. Recombinant full-length tissue factor pathway inibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost 1996; 76: 615-20.
• 3 Sandset PM. Tissue factor pathway inhibitor (TFPI) – an update. Haemostasis 1996; 26 (Suppl. 04) 154-65.
• 4 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principle site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
• 5 Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
• 6 Novotny WF. Tissue factor pathway inhibitor. Semin Thromb Haemost 1994; 20: 101-8.
• 7 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
• 8 Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52.
• 9 Lietz H, Hoppensteadt D, Jeske W, Amiral J, Wolf H, Fareed J. Heparin and LMW heparin not only release TFPI from endogenous vascular sites but also favor the equilibrium of free TFPI. Blood 1997; 11 (Suppl. 01) 119b (Abstract).
• 10 Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-9.
• 11 Zitoun D, Bara L, Bloch MF, Samama MM. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res 1994; 75: 577-80.
• 12 Hinz U, Grulich-Henn J, Preissner KT, Müller-Berghaus G. Mechanism of extrinsic pathway inhibitor stimulation by heparin in umbilical vein endothelial cells. Thromb Haemost 1991; 66: 952 (abstract).
• 13 Lupu C, Kanthou C, Lupu F, Kakkar VV. Heparin induces release of intra-cellular tissue pathway inhibitor from human endothelial cells in culture. Thromb Haemost. 1997 (suppl): 565 (Abstract).
• 14 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439-49.
• 15 Harenberg J, Jeschek M, Acker M, Malsh R, Huhle G, Heene DL. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Blood Coagul Fibrinolysis 1996; 7: 49-56.
• 16 Mauray S, Sternberg C, Theveniaux J, Millet J, Sinquin C, TaponBretaudiere J, Fischer AM. Venous antithrombotic and anticoagulant activities of a fucoidan fraction. Thromb Haemost 1995; 74: 1280-5.
• 17 Jaffe EA, Nachman EL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
• 18 Warn-Cramer BJ, Almus FE, Rapaport SI. Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemost 1989; 61: 101-5.
• 19 Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-7.
• 20 Glabe CG, Yednock T, Rosen SD. Reversible disruption of cultured endothelial monolayers by sulphated fucans. J Cell Sci 1983; 61: 475-90.